Cancer Radiotherapie最新文献

{"title":"Radiochirurgie des névralgies trigéminales avec accélérateur linéaire dédié sans cadre invasif : de la mise en service de l’appareil aux premiers résultats cliniques","authors":"É. Queyrel ,&nbsp;M. Lanaret ,&nbsp;T. Khalil ,&nbsp;M. Al Gahatany ,&nbsp;R. Chaix ,&nbsp;J.-J. Lemaire ,&nbsp;X. Moisset ,&nbsp;V. Chassin ,&nbsp;L. Brun ,&nbsp;V. Dedieu ,&nbsp;J. Biau","doi":"10.1016/j.canrad.2023.07.017","DOIUrl":"10.1016/j.canrad.2023.07.017","url":null,"abstract":"<div><h3>Purpose</h3><p>Radiosurgery for the treatment of trigeminal neuralgia delivers a very high dose in a single fraction, over a few millimeters, at a single isocenter placed along the nerve. We present here the different steps that have been performed to validate small beams by conical collimators, and report the clinical results of the first patients treated on Novalis Tx®, frameless.</p></div><div><h3>Material and methods</h3><p>First, the geometric accuracy of 4 and 6<!--> <!-->mm conical collimators was evaluated using Winston-Lutz tests; then dosimetric data acquisition was performed using high spatial resolution detectors (PTW 60019 microdiamond and a PTW 60017 E-diode). The corrective factors of the TRS 483 report were applied to calculate the collimator aperture factors. These dosimetric data were then compared with the data implemented in the iPlan® treatment planning system. Then end-to-end tests were performed to control the entire treatment process using an anthropomorphic phantom “STEEV”. Between 2020 and 2022, 18 patients were treated for refractory trigeminal neuralgia on Novalis Tx®, frameless, with Exactrac® repositioning. A total of 17 patients were evaluated (one was lost to follow-up) using the BNI score for pain assessment and MRI with a median follow-up of 12 months.</p></div><div><h3>Results</h3><p>The quality criteria of geometric and dosimetric accuracy were met for the 6-mm cone but not for the 4-mm cone. All patients were treated with a 6-mm cone with a dose of 90<!--> <!-->Gy prescribed at the isocenter at the root entry zone. Initial pain control was obtained in 70.5% of our patients, and 53% maintained pain control with a median follow-up of 12 months. All recurrences occurred within 3 to 6 months after radiosurgery. No brainstem toxicity was observed. Six patients had non-disabling facial hypoesthesia, half of whom already had pretreatment hypoesthesia.</p></div><div><h3>Conclusion</h3><p>The treatment of trigeminal neuralgia on a dedicated linear accelerator is a highly technical treatment whose accuracy and safety are paramount. The physical measurements allowed the commissioning of the technique with a 6<!--> <!-->mm cone. Our first clinical results are in accordance with the literature.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 2","pages":"Pages 164-173"},"PeriodicalIF":1.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140137618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of deep learning in radiation therapy for cancer","authors":"X. Wen ,&nbsp;C. Zhao ,&nbsp;B. Zhao ,&nbsp;M. Yuan ,&nbsp;J. Chang ,&nbsp;W. Liu ,&nbsp;J. Meng ,&nbsp;L. Shi ,&nbsp;S. Yang ,&nbsp;J. Zeng ,&nbsp;Y. Yang","doi":"10.1016/j.canrad.2023.07.015","DOIUrl":"10.1016/j.canrad.2023.07.015","url":null,"abstract":"<div><p>In recent years, with the development of artificial intelligence, deep learning has been gradually applied to clinical treatment and research. It has also found its way into the applications in radiotherapy, a crucial method for cancer treatment. This study summarizes the commonly used and latest deep learning algorithms (including transformer, and diffusion models), introduces the workflow of different radiotherapy, and illustrates the application of different algorithms in different radiotherapy modules, as well as the defects and challenges of deep learning in the field of radiotherapy, so as to provide some help for the development of automatic radiotherapy for cancer.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 2","pages":"Pages 208-217"},"PeriodicalIF":1.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140190487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erectile function preservation after radiotherapy using a dose-optimization approach on sexual structures for localized prostate cancer","authors":"A. Chardon ,&nbsp;C. Udrescu ,&nbsp;A. Beneux ,&nbsp;A. Ruffion ,&nbsp;S. Horn ,&nbsp;A. Lapierre ,&nbsp;O. Chapet","doi":"10.1016/j.canrad.2023.08.010","DOIUrl":"https://doi.org/10.1016/j.canrad.2023.08.010","url":null,"abstract":"<div><h3>Purpose</h3><p>Erectile function preservation is an important quality of life factor in patients treated for prostate cancer. A dose-optimization approach on sexual structures was developed and evaluated to limit erectile dysfunction after radiotherapy.</p></div><div><h3>Materials and methods</h3><p>Twenty-three men with localized prostate cancer and no erectile dysfunction were enrolled in the study. All patients received a prescription dose between 76 and 78<!--> <!-->Gy. Computed tomography/magnetic resonance image registration was used to delineate the prostatic volume and the sexual structures: internal pudendal arteries (IPA), penile bulb and corpus cavernosum. Erectile function was evaluated using the 5-items International Index of Erectile Function (IIEF-5) score every 6 months during the 2 years after radiotherapy and once a year afterwards. No erectile dysfunction, mild erectile dysfunction and severe erectile dysfunction were defined if the IIEF-5 scores were 20–25, 17–19 and &lt; 17, respectively.</p></div><div><h3>Results</h3><p>The mean follow-up was 4.5 years. The mean age of the patients was 66.3 years. At 2 years, 67% of the patients had no erectile dysfunction, 11% had mild erectile dysfunction and 22% had severe erectile dysfunction. No significant difference was found between the patients with and without erectile dysfunction (IIEF-5<!--> <!-->≥<!--> <!-->20 and IIEF-5<!--> <!-->&lt;<!--> <!-->20, respectively) for any of the parameters: dosimetric values (internal pudendal arteries, penile bulb, corpus cavernosum), age, comorbidity and smoking status. The biochemical-relapse free survival was 100% at 2 years.</p></div><div><h3>Conclusion</h3><p>This approach with dose-optimization on sexual structures for localized prostate cancer found excellent results on erectile function preservation after radiotherapy, with 78% of the patients with no or mild erectile dysfunction at 2 years.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 2","pages":"Pages 182-187"},"PeriodicalIF":1.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140605892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of adjuvant radiotherapy and chemotherapy on thymoma","authors":"J. Dumont ,&nbsp;J. Bou-Gharios ,&nbsp;A. Keller ,&nbsp;I. Chambrelant ,&nbsp;G. Pamart ,&nbsp;C. Mascaux ,&nbsp;P.-E. Falcoz ,&nbsp;D. Antoni ,&nbsp;A. Olland ,&nbsp;G.A. Pietta ,&nbsp;G. Noël","doi":"10.1016/j.canrad.2023.08.009","DOIUrl":"10.1016/j.canrad.2023.08.009","url":null,"abstract":"<div><h3>Purpose</h3><p>Thymoma is a rare tumour. The most common treatment for thymoma is surgical resection, while the use of radiotherapy and chemotherapy remains controversial.</p></div><div><h3>Patients and methods</h3><p>We conducted a monocentric observational study of 31 patients diagnosed with thymoma from June 2004 to July 2020 at cancer centre in Strasbourg, France. We analysed the outcomes of the patients.</p></div><div><h3>Results</h3><p>The 2- and 5- year locoregional relapse-free survival rates were 96.3% (95% confidence interval [CI]: 76.5–99.5%) and 68.0% (95% CI: 43.8–83.5%), respectively. Radiotherapy and chemotherapy significantly improved local tumour control (<em>P</em> <!-->=<!--> <!-->0.0008 and 0.04, respectively), while a larger initial tumour size significantly worsened local control rates (<em>P</em> <!-->=<!--> <!-->0.04). The 5- and 10-year overall survival rates were 87.1% (95% CI: 69.2–95%) and 81.7% (95% CI: 60.3–92.2%), respectively. The median overall survival was not reached, and no favourable factor was retrieved. For relapsed patients, the median overall survival after relapse was 115 months.</p></div><div><h3>Conclusion</h3><p>Despite the inherent limitations of retrospective studies with a limited patient sample size, we demonstrated that chemotherapy and radiotherapy in addition to surgery were effective in achieving local control and contributed to improving patient outcomes in thymoma. Notably, an aggressive treatment strategy at the time of relapse resulted in favourable outcomes for retreated patients.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 2","pages":"Pages 174-181"},"PeriodicalIF":1.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139096167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality control of postoperative radiotherapy for non-small cell lung cancer: A study of mediastinal shift","authors":"W. Zhang ,&nbsp;Y. Zhang ,&nbsp;W.-W. Ouyang ,&nbsp;S. Fa Su ,&nbsp;Z. Ma ,&nbsp;Q.-S. Li ,&nbsp;W. Gang Yang ,&nbsp;X. Xia Chen ,&nbsp;J. Liu ,&nbsp;B. Lu","doi":"10.1016/j.canrad.2023.06.032","DOIUrl":"10.1016/j.canrad.2023.06.032","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Purpose&lt;/h3&gt;&lt;p&gt;This study aimed to assess the shifting patterns of the mediastinum, including the target volume and the isocenter point during the postoperative radiotherapy (PORT) process of non-small cell lung cancer (NSCLC), and to observe the occurrence of radiation injury. Additionally, we investigated the significance of mid-term assessment during the implementation of the PORT process.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Material and methods&lt;/h3&gt;&lt;p&gt;We established coordinate axes based on bone anatomy and measured the mediastinum's three-dimensional direction and the shift of the isocenter point's shift in the PORT process. Statistical analysis was performed using Wilcoxon, Kruskal-Wallis, and the Chi-square test. &lt;em&gt;P&lt;/em&gt; &lt;!--&gt;&lt;&lt;!--&gt; &lt;!--&gt;0.05 was considered statistically significant.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;p&gt;In this study, the analysis of patients revealed that the shift of anterior and posterior mediastinum (X), left and right mediastinum (Y), upper and lower mediastinum (Z), anterior and posterior isocenter point (X&lt;sub&gt;i&lt;/sub&gt;), and the left and right isocenter points (Y&lt;sub&gt;i&lt;/sub&gt;) in the PORT process were 0.04–0.53, 0.00–0.84, 0.00–1.27, 0.01–0.86, and 0.00–0.66&lt;!--&gt; &lt;!--&gt;cm, respectively. The shift distance of the mediastinum was Z&lt;!--&gt; &lt;!--&gt;&gt;&lt;!--&gt; &lt;!--&gt;Y&lt;!--&gt; &lt;!--&gt;&gt;&lt;!--&gt; &lt;!--&gt;X, and the shift distance of the isocenter point was X&lt;sub&gt;i&lt;/sub&gt; &lt;!--&gt;&gt;&lt;!--&gt; &lt;!--&gt;Y&lt;sub&gt;i&lt;/sub&gt;. According to the ROC curve, the cut-off values were 0.263, 0.352, 0.405, 0.238, and 0.258, respectively, which were more significant than the cut-off values in 25 cases (25%), 30 cases (30%), 30 cases (30%), 17 cases (17%), and 15 cases (15%). In addition, there was a significant difference in the shift of the mediastinum and the isocenter point (all &lt;em&gt;P&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.00). Kruskal-Wallis test showed no statistically significant difference between mediastinal shift and resection site in X, Y, and Z directions (&lt;em&gt;P&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.355, &lt;em&gt;P&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.239, &lt;em&gt;P&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.256), surgical method (&lt;em&gt;P&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.241, &lt;em&gt;P&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.110, &lt;em&gt;P&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.064). There was no significant difference in the incidence of RE and RP in PORT patients (&lt;em&gt;P&lt;/em&gt; &lt;!--&gt;&gt;&lt;!--&gt; &lt;!--&gt;0.05). No III–IV RP occurred. However, the incidence of ≥ grade III RE in the modified plan cases after M-S was significantly lower than in the original PORT patients, 0% and 7%, respectively (&lt;em&gt;P&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.000).&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;p&gt;In conclusion, this study provides evidence that mediastinal shift is a potential complication during the PORT process for patients with N2 stage or R1–2 resection following radical resection of NSCLC. This shift affects about 20–30% of patients, manifesting as actual radiation damage to normal tissue and reducing the local control rate. Therefore, mid-term repositioning of the PORT and revision of the target volume and radiation thera","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 2","pages":"Pages 152-158"},"PeriodicalIF":1.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139699133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interstitial brachytherapy for lip carcinomas: Comparison between Ir-192 low-dose-rate and high-dose-rate treatment","authors":"M. Cuenin ,&nbsp;J. Salleron ,&nbsp;D. Peiffert ,&nbsp;É. Meknaci ,&nbsp;P. Gallet ,&nbsp;Y. Abushama ,&nbsp;J.-F. Py ,&nbsp;S. Renard","doi":"10.1016/j.canrad.2023.06.031","DOIUrl":"10.1016/j.canrad.2023.06.031","url":null,"abstract":"<div><h3>Purpose</h3><p>Low-dose-rate (LDR) and high-dose-rate (HDR) interstitial brachytherapy are known to be effective in the treatment of lip carcinomas. The aim of this study was to retrospectively compare oncologic and toxicity outcomes between the two techniques.</p></div><div><h3>Patients and methods</h3><p>From 2007 to 2018, patients at the Institut de cancérologie de Lorraine (France) who received exclusive or adjuvant interstitial brachytherapy for lip squamous carcinomas were studied. Two groups were defined: the LDR/PDR group, including patients treated with iridium-192 wires, or pulsed-dose rate technique, and the high-dose-rate group, with patients treated by high-dose-rate technique. The dose ranged between 50<!--> <!-->Gy and 65<!--> <!-->Gy (depending on previous surgery) for low-dose-/pulsed-dose rate treatments, and 39<!--> <!-->Gy for high-dose-rate (twice a day). Early, late toxicity events and oncologic control were reported.</p></div><div><h3>Results</h3><p>Among the 61 patients whose data were analyzed retrospectively, 36 received the low-dose-/pulsed-dose rate treatment (59%) and 25 the high-dose-rate brachytherapy (41%). The median follow-up time was 44 months. At 36 months, the local control rates were 96.3% for LDR/PDR group and 100% for HDR (<em>P</em> <!-->=<!--> <!-->0.180). The regional control rates were 85.9% and 92% without any difference according to the two groups (<em>P</em> <!-->=<!--> <!-->0.179). The specific overall survival rate was 95.5% with no difference between groups. There were more grade 2 or higher mucositis in the HDR group than in LDR/PDR group (40% versus 16.7%, <em>P</em> <!-->=<!--> <!-->0.042). One case of grade 3 mucositis was recorded in each group. No grade 3 late complications were recorded. High-dose-rate brachytherapy reduced the length of hospitalization by 2 days (<em>P</em> <!-->&lt;<!--> <!-->0.001).</p></div><div><h3>Conclusion</h3><p>High-dose- or low-dose-/pulsed-dose rate brachytherapy seemed to be as effective and well tolerated in our experience of 61 patients.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 2","pages":"Pages 145-151"},"PeriodicalIF":1.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138568530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comments on “An umbrella review exploring the effect of radiotherapy for head and neck cancer patients on the frequency of jaws osteoradionecrosis”","authors":"B. Yilmaz ,&nbsp;U. Selek","doi":"10.1016/j.canrad.2023.07.016","DOIUrl":"10.1016/j.canrad.2023.07.016","url":null,"abstract":"","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 2","pages":"Pages 206-207"},"PeriodicalIF":1.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140133528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2023 A new French revolution: Organ preservation for rectal cancer","authors":"J.-P. Gérard","doi":"10.1016/j.canrad.2024.02.001","DOIUrl":"10.1016/j.canrad.2024.02.001","url":null,"abstract":"","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 2","pages":"Pages 143-144"},"PeriodicalIF":1.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140178179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proposition de délinéation des volumes cibles anatomocliniques postopératoires de la tumeur primitive des cancers du sinus maxillaire et des cavités nasales","authors":"F. Guillemin ,&nbsp;P. Blanchard ,&nbsp;P. Boisselier ,&nbsp;Y. Brahimi ,&nbsp;V. Calugaru ,&nbsp;A. Coutte ,&nbsp;P. Gillon ,&nbsp;P. Graff ,&nbsp;X. Liem ,&nbsp;A. Modesto ,&nbsp;Y. Pointreau ,&nbsp;S. Racadot ,&nbsp;X.S. Sun ,&nbsp;R. Bellini ,&nbsp;N. Pham Dang ,&nbsp;N. Saroul ,&nbsp;J. Bourhis ,&nbsp;J. Thariat ,&nbsp;J. Biau ,&nbsp;M. Lapeyre","doi":"10.1016/j.canrad.2023.12.001","DOIUrl":"https://doi.org/10.1016/j.canrad.2023.12.001","url":null,"abstract":"<div><p>In this article, we propose a consensus delineation of postoperative clinical target volumes for the primary tumour in maxillary sinus and nasal cavity cancers. These guidelines are developed based on radioanatomy and the natural history of those cancers. They require the fusion of the planning CT with preoperative imaging for accurate positioning of the initial GTV and the combined use of the geometric and anatomical concepts for the delineation of clinical target volume for the primary tumour. This article does not discuss the indications of external radiotherapy (nor concurrent systemic treatment) but focuses on target volumes when there is an indication for radiotherapy.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 2","pages":"Pages 218-227"},"PeriodicalIF":1.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140605937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute toxicity in patients with high-risk prostate cancer treated with stereotactic body radiation, with irradiation to the prostate and pelvic nodes","authors":"S. Faria ,&nbsp;M. Duclos ,&nbsp;F. Cury ,&nbsp;H. Patrocinio ,&nbsp;L. Souhami","doi":"10.1016/j.canrad.2023.07.014","DOIUrl":"10.1016/j.canrad.2023.07.014","url":null,"abstract":"<div><h3>Purpose</h3><p>Stereotactic body radiation therapy has been used for prostate cancer. However, the bulk of published studies on stereotactic body radiation therapy for prostate cancer has involved the irradiation of the prostate alone, without irradiation of the pelvic lymph nodes. We report our preliminary experience with this approach.</p></div><div><h3>Material and methods</h3><p>The files of patients with biopsy-proven prostate cancer treated with stereotactic body radiation therapy in our institution were reviewed. Stereotactic body radiation was delivered with intensity modulated-volumetric arctherapy with daily image-guidance. The prostate planning target volume included the prostate plus a margin of 5<!--> <!-->mm in all directions. The pelvic planning target volume included pelvic nodes plus an expansion of 6 to 7<!--> <!-->mm in all directions. The prostate planning target volume received a total dose of 36.25<!--> <!-->Gy delivered in five fractions on alternate days. The nodal planning target volume received a dose of 25<!--> <!-->Gy in the same five fractions. Patients were followed during treatment, after 1, and 3 months and every 6 months thereafter. Gastrointestinal and genitourinary toxicity was prospectively graded according to Common Terminology Criteria for Adverse Events.</p></div><div><h3>Results</h3><p>Among the 188 patients, 80 received stereotactic body radiation to the prostate and the pelvic nodes, while 108 received stereotactic body radiation to the prostate target only. Grade 2 acute gastrointestinal toxicity was 4% in both groups, and grade 2 acute genitourinary toxicity was 27% and 20% (<em>P</em> <!-->=<!--> <!-->0.9) for prostate only versus prostate and pelvis respectively. There was no grade 3 or higher acute gastrointestinal or genitourinary toxicity.</p></div><div><h3>Conclusion</h3><p>Stereotactic body radiation therapy in five fractions including the prostate and pelvic nodes, in patients with high-risk prostate cancer, has been feasible and safe in terms of acute toxicity.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 2","pages":"Pages 159-163"},"PeriodicalIF":1.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140320122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}